Drug Type Universal CAR-T |
Synonyms- |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Gene transference, T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CD19-positive B-cell acute lymphoblastic leukemia | Phase 2 | CN | 31 Dec 2023 | |
Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | CN | 31 Dec 2023 | |
Refractory B Acute Lymphoblastic Leukemia | Phase 2 | CN | 31 Dec 2023 | |
Acute Lymphoblastic Leukemia | Preclinical | CN | - |